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Abstract 
This data article accompanies the manuscript entitled: “Prothrombotic Disturbances of Hemostasis of 
Patients with Severe COVID-19: a Prospective Longitudinal Observational Cohort Study” submitted to 
Thrombosis Research by the same authors. We report temporal changes of plasma levels of an extended 
set of laboratory parameters during the ICU stay of the 21 COVID-19 patients included in the 
monocentre cohort: CRP, platelet count, prothrombin time; Clauss fibrinogen and clotting factors II, V 
and VIII levels, D-dimers, antithrombin activity, protein C, free protein S, total and free tissue factor 
pathway inhibitor, PAI-1 levels, von Willebrand factor antigen and activity, ADAMTS-13 (plasma levels); 
and of two integrative tests of coagulation (thrombin generation ST Genesia) and fibrinolysis (global 
fibrinolytic capacity - GFC). Regarding hemostasis, we used double-centrifuged frozen citrated plasma 
prospectively collected after daily performance of usual coagulation tests. Demographic and clinical 
characteristics of patients and thrombotic and hemorrhagic complications were also collected from 
patient’s electronic medical reports. 
 
Keywords 
COVID-19, intensive care unit, thrombin generation, fibrinolysis, thrombosis, D-dimers, hemostasis 
plasma proteins.  
 
  
         
Specifications Table  
 
Subject Haematology 
Specific subject area Haemostasis, Coronavirus disease 2019 
Type of data Tables 
Figures 
How data were acquired Blood samples prospectively collected daily from intensive care unit (ICU) 
patients admitted for coronavirus disease 2019 (COVID-19). 
Corresponding instruments and reagents of laboratory hematology for: 
platelet count, prothrombin time, Clauss fibrinogen and clotting factors II, 
V and VIII levels, D-dimers levels, PAI-1 levels, antithrombin activity, 
protein C activity, free protein S antigen, total and free tissue factor 
pathway inhibitor antigens, von Willebrand factor antigen and activity, 
ADAMTS-13 levels), thrombin generation, and global fibrinolytic capacity 
(GFC); and C-reactive protein. 
Data format Raw: Public repository 
Analyzed: Tables and figures 
Parameters for data 
collection 
Laboratory data: Clinical laboratory tests that describe disturbances of 
haemostasis of ICU patients, severely affected with CoViD-19: primary 
haemostasis (platelet count, von Willebrand factor antigen and activity; 
ADAMTS-13 activity); coagulation (prothrombin time, Clauss fibrinogen, 
clotting factors II, V and VIII levels, in vitro thrombin potential), natural 
anticoagulants (antithrombin activity, protein C activity, free protein S 
antigen, total and free tissue factor pathway inhibitor antigens); and 
fibrinolysis (D-dimers levels, PAI-1 activity, global fibrinolytic capacity). 
Clinical data: complications of hemostasis disturbances (thrombosis and 
hemorrhages) and relevant data for characterization of the cohort (age; 
sex, BMI, ethnicity, comorbidities, APACHE II, SOFA scores and PaO2/FiO2 
ratios at ICU admission, ICU stay duration, anticoagulation regimen, ICU 
length of stay, need for respiratory, cardiocirculatory or renal support; 
death). 
Description of data 
collection 
The following laboratory tests were performed with a STA-R Max 
(Diagnostica Stago, Asnières-sur-Seine) and reagents from Stago: 
prothrombin time (STA-NeoPTimal), Clauss fibrinogen (STA-Liquid FIB), 
clotting factor II (STA-NeoPTimal and STA – Deficient II), V (STA-
NeoPTimal and STA – Deficient V) and VIII (STA-CK Prest and STA – 
         
Immunodef VIII), D-dimers (STA – LIATEST D-Di Plus), PAI-1 (STACHROM 
PAI-1), antithrombin (STA-Stachrom ATIII), protein C activity (STA – 
Stachrom Protein C), free protein S antigen (STA-LIATEST Free Protein S), 
total (Asserachrom total TFPI) and free TFPI (Asserachrom free TFPI), 
heparin anti-Xa activity (STA - Liquid anti-Xa), von Willebrand factor 
antigen (STA – LIATEST VWF:Ag). 
CRP levels were measured on a Vitros 5600 Integrated System with CRP 
Gold Latex reagents (DiAgam, Ghislenghien, Belgium) and platelet count 
on a Sysmex XN-20 analyzer with Cellpack reagent (Sysmex). Thrombin 
generation was measured on a ST Genesia with STG-ThromboScreen 
reagent (Stago) after neutralizing heparin with hexadimethrine bromide 
(25μg/mL; polybrene, Sigma Aldrich, Saint-Louis, United States). Global 
fibrinolytic capacity was measured using the Lysis Timer instrument with 
dedicated reagents (Hyphen Biomed). ADAMTS13 activity was measured 
using the Technozym® ADAMTS-13 Activity ELISA kit (Technozym, 
Technoclone, Vienna, Austria). Von Willebrand activity was measured on 
an AcuStar analyser with HemosIL AcuStar VWF:RCo reagent 
(Instrumentation Laboratory). 
 
Laboratory data were retrieved from laboratory files. Clinical data were 
retrieved from patients’ medical charts. 
Data source location Institution: CHU UCL Namur – Godinne site 
City: Yvoir 
Country: Belgium 
Data accessibility Repository name: Mendeley Data 
Data identification number: 10.17632/g7x5nvj9d2.1 
Direct URL to data: https://dx.doi.org/10.17632/g7x5nvj9d2.1 
Related research article  M. Hardy, I. Michaux, S. Lessire, J. Douxfils, J.-M. Dogné, M. Bareille, G. 
Horlait, P. Bulpa, C. Chapelle, S. Laporte, S. Testa, H. Jacqmin, T. 
Lecompte, A. Dive and F. Mullier. Prothrombotic Hemostasis Disturbances 
in Patients with Severe COVID-19: a Prospective Longitudinal 
Observational Cohort Study. Thromb Res. In Press. [1] 
 
 
Value of the Data 
• The data reported with individual time-courses during the ICU stay show the variability of 
hemostasis parameters over time and between individuals, suggesting varying thrombotic risks and the 
need for individualization with frequent reassessment of thrombotic prophylaxis. 
• They can benefit to all physicians and scientists dealing with CoViD-19. 
         
• These data will be helpful to design further prospective studies focusing on COVID-19 




Demographic and clinical characteristics of observed ICU patients are shown in Table 1. Values 
correspond to median (with interquartile and min-max ranges) for quantitative data and to number 
(percent) for qualitative data.  
 
Baseline (D0) was defined as ICU admission (in Namur or elsewhere; 11 patients were transferred from 
the ICU of another Belgian hospital), but the laboratory-monitoring period was restricted to the Namur 
ICU stay. Tests on D0 were often missing due to delays in patients’ inclusion. 
 
Table 2 represents the changes over time of hemostasis parameters along ICU stay of 21 severe COVID-
19 patients. Observation period has been arbitrarily subdivided into three time-intervals of 10 days 
starting from D1. For each patient and time-interval, parameters medians were calculated. Medians and 
interquartile ranges of patient’s medians are presented for the three time-intervals. Minimum and 
maximum values observed are also represented. D-dimers plasma levels are expressed in fibrinogen 
equivalent units (FEU) and ‘reference ranges’ depicted correspond to DIC thresholds according to the 
ISTH definition with the reagents we used [2]. 
 
The figures represent the changes over time of measured hemostasis parameters during the ICU stay of 
each of the 21 patients. Blue lines represent the reference range locally determined, or previously 
published under similar analytical conditions, or according to the manufacturer’s (see figure legends). 
Stars represent the follow-up period of the patients; orange stars represent the day of diagnosis of a 
thrombotic complication (which might be delayed form the actual onset). 
  
         
Table 1: Demographic and clinical characteristics of observed patients 
 All patients  
(n=21) 
Age (years), median (IQR) 60 [57–64] 
(48-74) 
Male gender, n (total) 18 (21) 
BMI (kg/m²), median (IQR) 30 [27–32] 
(21-42) 
Caucasian ethnicity, n (total) 18 (21) 
Obesity (BMI ≥30 kg/m²), n (total) 11 (21) 
Hypertension, n (total) 11 (21) 
COPD, n (total) 4 (21) 
Asthma, n (total) 3 (21) 
CAD, n (total) 3 (21) 
On arrival at the ICU 
APACHE II, median (IQR) 14 [12–20] 
(9-22) 
SOFA score, median (IQR) 6 [4–8] 
(3-12) 
Time-interval between symptoms onset 
and ICU admission, median (IQR) 
9 [8–11] 
(4-15) 
PAFI, median (IQR) 91 [67–135] 
(44-260) 
         
 All patients  
(n=21) 
During ICU stay 
ICU stay duration, median (IQR) 15 (7-26) 
(5-28) 
Patients having received UFH*, n (total) 13 (21) 
UFH daily dose (IU/kg/day), median (IQR) 441 [338–587] 
(0-800) 
Patients having received LMWH, n (total) 19 (21) 
LMWH daily dose (IU/kg/day), median (IQR) 100 [53–149] 
(0-230) 
Non-invasive ventilation, n (tot) 3 (21) 
Invasive ventilation support, n (tot) 19 (21) 
ECMO, n (tot) 5 (21) 
Vasopressor use, n (tot) 16 (21) 
New renal replacement therapy, n (tot) 6 (21) 
Thrombotic complications** 10 (21) 
Major bleeding according to the ISTH** 6 (21) 
Death, n (tot) 3 (21) 
Discharged from ICU at the end of observation period, n (tot) 9 (21) 
* Patients may have received UFH or LMWH at different periods of ICU stay. 
** See the companion paper for the descriptions of the events. 
         
IQR, interquartile range; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CAD, 
coronary artery disease; ICU, intensive care unit; IQR, interquartile range; APACHE II score, acute 
physiology and chronic health disease classification system II; SOFA, sepsis-related organ failure 
assessment; PAFI, PaO2/FiO2 ratio; UFH, unfractionated heparin; LWMH, low molecular weight heparin; 







         
Table 2: Changes over time of hemostasis parameters along intensive care unit stay. 
Variable and 
reference ranges  
D1–D10 
(n = 18) 
D11–D20 
(n = 15) 
D21–D30 













150 to 450  
246 [177–387] 
(73–701) 




vWF antigen (%) 
50 to 160 






vWF activity (%) 
















Prothrombin time (%) 















Factor II (%) 







Factor V (%) 







Factor VIII (%) 















         
Variable and 
reference ranges  
D1–D10 
(n = 18) 
D11–D20 
(n = 15) 
D21–D30 
(n = 9) 








Free protein S antigen (%) 
Men: 70 to 148 







Total TFPI (ng/mL) 







Free TFPI (ng/mL) 







Thrombin generation  
lag time (ratio) 







Thrombin generation  
time to peak (ratio) 







Thrombin generation  
peak height (%) 








Thrombin generation  
ETP (%) 








D-dimers  (ng/mL) 
ISTH criterion for DIC, ≥3,500 (2 pts)  










PAI-1 (AU/mL) 23.6 [20.3–25.4] 19.5 [16.5–28.8] 15.6 [13.9–57.2] 
         
Variable and 
reference ranges  
D1–D10 
(n = 18) 
D11–D20 
(n = 15) 
D21–D30 
(n = 9) 
<16  (2.3–58.7) (1.6–52.0) (6.8–52.2) 
GFC (min) 







CRP, C-reactive protein; vWF antigen, von Willebrand factor antigen; vWF activity, von Willebrand factor 
activity, ristocetin cofactor; ADAMTS-13 (also known as von Willebrand factor cleaving protease); TFPI, 
tissue factor pathway inhibitor; DIC, disseminated intravascular coagulopathy; t-PA, tissue-type 
plasminogen activator; PAI-1, plasminogen activator inhibitor; AU, arbitrary units; GFC, global fibrinolysis 
capacity (Lysis Timer instrument); ETP, endogenous thrombin potential. 
Results of ST Genesia TGA are relative to reference plasma and expressed as ratios (temporal 
parameters) or percentages (thrombin concentration-related parameters). 
 
  
         
 
 
Figure 1: Temporal changes in C-reactive protein plasma levels during Namur ICU stay for the 21 
patients. Each point represents the result of the test of the day. The blue line represents the reference 
range according to the manufacturer (5mg/dL). Grey stars represent the inclusion period and orange 
stars the day of thrombosis diagnosis. 
 
 
Figure 2: Temporal changes in platelet count during Namur ICU stay for the 21 patients. Each point 
represents the result of the test of the day. Blue lines represent the reference range (150-450 x 109/L). 
Grey stars represent the inclusion period and orange stars the day of thrombosis diagnosis. 
 
         
 
Figure 3: Temporal changes in prothrombin time (expressed as percentage activity) during Namur ICU 
stay for the 21 patients. Each point represents the result of the test of the day. Blue lines represent the 
reference range locally determined (75-100%). Grey stars represent the inclusion period and orange 
stars the day of thrombosis diagnosis. 
 
 
Figure 4: Temporal changes in Clauss fibrinogen during Namur ICU stay for the 21 patients. Each point 
represents the result of the test of the day. Blue lines represent the reference range according to the 
manufacturer (200-400mg/dL). Grey stars represent the inclusion period and orange stars the day of 
thrombosis diagnosis. 
 
         
 
Figure 5: Temporal changes in clotting factor II levels during Namur ICU stay for the 21 patients. Each 
point represents the result of the test of the day. Blue lines represent the reference range according to 





Figure 6: Temporal changes in clotting factor V levels during Namur ICU stay for the 21 patients. Each 
point represents the result of the test of the day. Blue lines represent the reference range according to 
the manufacturer (70-120%). Grey stars represent the inclusion period and orange stars the day of 
thrombosis diagnosis. 
 
         
 
Figure 7: Temporal changes in clotting factor VIII levels during Namur ICU stay for the 21 patients. Each 
point represents the result of the test of the day. Blue lines represent the reference range according to 




Figure 8: Temporal changes in D-dimers plasma levels during Namur ICU stay for the 21 patients. Each 
point represents the result of the test of the day. Grey stars represent the inclusion period and orange 
stars the day of thrombosis diagnosis. 
 
         
 
Figure 9: Temporal changes in thrombin generation (ST Genesia with ThromboScreen reagent) lag time 
(LT) normalized using a reference plasma (provided with ThromboScreen reagent) during Namur ICU 
stay for the 21 patients. Each point represents the result of the test of the day. Blue lines represent the 
reference range according to Calzavarini et al (1.1-1.3) [3]. Grey stars represent the inclusion period and 
orange stars the day of thrombosis diagnosis. The ordinate is represented using a logarithmic scale. 
 
 
Figure 10: Temporal changes in thrombin generation (ST Genesia with ThromboScreen reagent) time to 
peak (ttP) normalized using a reference plasma (provided with ThromboScreen reagent) during Namur 
ICU stay for the 21 patients. Each point represents the result of the test of the day. Blue lines represent 
the reference range according to Calzavarini et al (1.2-1.3) [3]. Grey stars represent the inclusion period 
and orange stars the day of thrombosis diagnosis. The ordinate is represented using a logarithmic scale. 
         
 
 
Figure 11: Temporal changes in thrombin generation (ST Genesia with ThromboScreen reagent) peak 
height (PH) normalized using a reference plasma (provided with ThromboScreen reagent) during Namur 
ICU stay for the 21 patients. Each point represents the result of the test of the day. Blue lines represent 
the reference range according to Calzavarini et al (45-66%) [3]. Grey stars represent the inclusion period 
and orange stars the day of thrombosis diagnosis.  
 
 
Figure 12: Temporal changes in thrombin generation (ST Genesia with ThromboScreen reagent) 
endogenous thrombin potential (ETP) normalized using a reference plasma (provided with 
ThromboScreen reagent) during Namur ICU stay for the 21 patients. Each point represents the result of 
         
the test of the day. Blue lines represent the reference range according to Calzavarini et al (59-80%) [3]. 
Grey stars represent the inclusion period and orange stars the day of thrombosis diagnosis. 
 
 
Figure 13: Temporal changes in PAI-1 activity during Namur ICU stay for the 21 patients. Each point 
represents the result of the test of the day. The blue line represents the reference range according to 




Figure 14: Temporal changes in global fibrinolytic capacity (GFC) measured with the Lysis Timer 
instrument during Namur ICU stay for the 21 patients. Each point represents the result of the test of the 
day. Blue lines represent the reference range locally determined (30-48min). Grey stars represent the 
         




Figure 15: Temporal changes in antithrombin activity during Namur ICU stay for the 21 patients. Each 
point represents the result of the test of the day. Blue lined represent the reference range according to 
the manufacturer (80-120%). Grey stars represent the inclusion period and orange stars the day of 





         
Figure 16: Temporal changes in protein C activity during Namur ICU stay for the 21 patients. Each point 
represents the result of the test of the day. Blue lines represent the reference range according to the 




Figure 17: Temporal changes in free protein S levels during Namur ICU stay for the 21 patients. Each 
point represents the result of the test of the day. Blue lines represent the reference range according to 





         
Figure 18: Temporal changes in total tissue factor pathway inhibitor (TFPI) levels during Namur ICU stay 
for the 21 patients. Each point represents the result of the test of the day. Blue lines represent the 
reference range according to the manufacturer (21.3-142.9ng/mL). Grey stars represent the inclusion 
period and orange stars the day of thrombosis diagnosis. 
 
 
Figure 19: Temporal changes in free tissue factor pathway inhibitor (TFPI) levels during Namur ICU stay 
for the 21 patients. Each point represents the result of the test of the day. Blue lines represent the 
reference range according to the manufacturer (0.4-19.6ng/mL). Grey stars represent the inclusion 




         
Figure 20: Temporal changes in von Willebrand factor (vWF) antigen levels during Namur ICU stay for 
the 21 patients. Each point represents the result of the test of the day. The blue line represents the 
reference range according to the manufacturer (< 160%). Grey stars represent the inclusion period and 
orange stars the day of thrombosis diagnosis. 
 
 
Figure 21: Temporal changes in von Willebrand factor (vWF) activity (ristocetin cofactor) during Namur 
ICU stay for the 21 patients. Each point represents the result of the test of the day. The blue line 
represents the reference range according to the manufacturer (< 176%). Grey stars represent the 
inclusion period and orange stars the day of thrombosis diagnosis. 
 
 
         
Figure 22: Temporal changes ADAMTS-13 activity during Namur ICU stay for the 21 patients. Each point 
represents the result of the test of the day. Blue lines represent the reference range according to the 




Experimental Design, Materials and Methods 
Setting 
CHU UCL Namur (Godinne site, Yvoir, Belgium), a tertiary academic hospital. 
 
Patients 
All patients admitted to the intensive care unit (ICU) of the CHU UCL Namur for an RT-PCR confirmed 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection from March 27 to April 24, 2020 
were considered for inclusion. Twenty-one patients were finally included, one patient being excluded 
because of major therapeutic limitation (i.e.. refusal of tracheal intubation). 
 
Clinical management 
Patients’ characteristics were collected at first ICU admission. Patients were managed according to local 
standard of care. Anticoagulation guidelines from the Groupe d’Intérêt en Hémostase Périopératoire 
(GIHP) were implemented in Namur from April 2, 2020 [4]. Patients were screened for deep vein 
thrombosis (DVT) within a week after Namur ICU admission, and then once a week unless a thrombotic 
event occurred. Pulmonary embolism (as a matter of fact could be in situ arterial thrombosis) was 
diagnosed directly by contract CT scan or indirectly by transesophageal ultrasonography (for unstable 
patients that cannot be transferred safely to the Radiology Department). Bleeding events were defined 
as minor or major according to ISTH definitions [5]. 
 
Blood samples 
Blood samples were collected from the arterial line as part of clinical patients’ care and at least once a 
day around 4a.m. Serum was prepared from plastic tubes containing alumina silicate as coagulation 
activator (Vacuette, Greiner Bio One, Kremsmünster, Austria), whole blood was collected in K2-
ethylenediaminetetraceatic acid (EDTA) tubes (Vacuette, Greiner Bio One) and plasma was prepared 
from 109mM citrate tubes (Vacuette, Greiner Bio One) using double centrifugation (1500g, 15min, room 




Laboratory tests were performed on 4a.m. samples whenever possible or on the temporally closest 
samples. 
CRP levels were measured on a Vitros 5600 Integrated System (Ortho Clinical Diagnostics, Belgium) with 
CRP Gold Latex reagents (DiAgam, Ghislenghien, Belgium) and platelet count on a Sysmex XN-20 
analyzer with Cellpack reagent (Sysmex Corporation, Kobe, Japan). 
         
The following laboratory tests were performed with a STA-R Max (Stago, Asnières-sur-Seine) and 
reagents from Stago: prothrombin time (STA-NeoPTimal; expressed as percentage [6]), Clauss fibrinogen 
(STA-Liquid FIB), clotting factor II (STA-NeoPTimal and STA – Deficient II), V (STA-NeoPTimal and STA – 
Deficient V) and VIII (STA-CK Prest and STA – Immunodef VIII), antithrombin (STA-Stachrom ATIII), D-
dimers (STA – LIATEST D-Di Plus), PAI-1 (STACHROM PAI-1), von Willebrand factor antigen (STA – 
LIATEST VWF:Ag), protein C activity (STA – Stachrom Protein C), free protein S antigen (STA-LIATEST Free 
Protein S), total (Asserachrom total TFPI) and free TFPI (Asserachrom free TFPI). 
Thrombin generation was measured with ST Genesia and STG-ThromboScreen reagent (Stago) after 
neutralizing heparin with hexadimethrine bromide (25μg/mL; polybrene, Sigma Aldrich, Saint-Louis, 
United States) [3, 7]. Global fibrinolytic capacity was measured using the Lysis Timer instrument (Hyphen 
Biomed, Neuville-sur-Oise, France; SD Innovation, Frouard, France, respectively) with dedicated 
reagents (Hyphen Biomed) [8]. ADAMTS-13 activity was measured using the Technozym® ADAMTS-13 
Activity ELISA kit (Technozym, Technoclone, Vienna, Austria). Von Willebrand activity was measured 
with an AcuStar analyser (Instrumentation Laboratory, Bedford, USA) and HemosIL AcuStar VWF:RCo 
reagent (Instrumentation Laboratory). 
Most analyses were intended to be performed once a day whenever possible. Some analyses were 
purposely performed only every 5 days (i.e. vWF antigen and activity, ADAMTS-13, total and free TFPI, 
tissue-type plasminogen activator) or every other day (protein C activity, free protein S antigen). The 
percentage of days with available data for the whole observation period is represented in Table 3. 
 
Analysis 
Graphs were performed in R (version 4.0.0) [9] using ggplot2 package (version 3.3.1). 
 
  
         
Table 3: Summary of percentages of available data over the observation period per laboratory 
parameter. 
Parameter Percentage of days with 
available data (%) 
C-reactive protein 97 
Platelet count 99 
Prothrombin time 85 
Fibrinogen 84 
Factor II 82 
Factor V 82 
Factor VIII 85 
D-dimers 84 
Thrombin generation LT 58 
Thrombin generation ttP 58 
Thrombin generation PH 58 




Global fibrinolytic capacity 83 
Antithrombin activity 84 
Protein C activity 44 
Free protein S antigen 44 
Total TFPI 33 
Free TFPI 33 
Anti-Xa activity 82 
von Willebrand factor antigen 21 








The observation was performed in accordance with the Declaration of Helsinki and after approval of the 
Ethics Committee of the CHU UCL Namur (NUB: B0392020000031). 
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